Abstract:Background: The ex vivo production of CD34+ hematopoietic progenitor cells from human bone-marrow mesenchymal stromal cells derived induced pluipotent stem cells (iPSCs) could serve as a feasible way to study patient-specific hematological disease from the perspective of hematopoietic differentiation. Different studies using virus-based or virus-free methods to reprogramming somatic cells into iPSCs by using fewer than four transcription factors, of which have the potential to differentiation in CD34+ hematopoietic progenitor cells. In this study, we demonstrate the generation of putative iPS cells from BMSCs with single OCT4 by plasmid transfection, which can differentiate into hematopoietic progenitor cells in defined culture system.Objective: To generate induced pluripotent stem cells (iPSCs) from bone marrow stromal cells (BMSCs) using a plasmid pcDNA3.1 constructed with a single transcription factor gene OCT4 (pcDNA3.1-OCT4) and to evaluate the hematopoietic differentiation potential of the putative BMSCs-iPSCs.Methods: BMSCs with ectopic high expression of OCT4 (BMSCs-OCT4) previously established by our group were cultured in traditional human ESC medium. Colonies with characteristic embryonic stem (ES) cell morphologies were selected and expanded in vitro. The undifferentiated status of putative BMSCs-iPSCs was confirmed by alkaline phosphatase (ALP) staining, telomerase activity assay, pluripotent marker expression and differentiation in vitro to form EBs and in vivo teratoma formation. The expression of pluripotent markers and ES markers were verified by RT-PCR, flow cytometry (FCM) and cellular immunofluorescence assay (CIFA). The hematopoietic differentiation potential into CD34+ progenitor cells by exposure to a defined culture system supplemented with a cocktail of hematopoietic growth factors was evaluated, of which the expression was confirmed by RT-PCR and FCM.Results: BMSCs were successfully reprogrammed into pluripotent stem cells resembling ESCs by introduction single transcription factor OCT4 gene constructed into the eukaryogenic plasmid pcDNA3.1. The putative BMSC-iPSCs were positive for ALP and telomerase activity, as well as the pluripotent stem cell markers including TRA-1-60, SSEA4, TRA-1-81, SOX2 and NANOG as detected by FCM and CIFA. Moreover, the above MSCs-OCT4 could form EBs ex vivo and express ectoderm (TUBB3+, WNT1+), mesoderm (Brachyury+, TBX20+), and endoderm (SPARC+) genes. By treatment with a cocktail containing BMP4 (50ng/ml), IL-3 (10ng/ml), IL-6 (10ng/ml), Flt-3 Ligand (300ng/ml), SCF (300ng/ml) and G-CSF (50ng/ml), the proportion of CD34+ progenitor cells increased from 0.93±0.46% in untransfected parental BMSCs and 1.58±1.29% in undifferentiated BMSC-iPS cells to 16.16±1.27% and 25.40±3.08% in day 14 and 21 differentiated BMSC-iPS cells, respectively. Moreover, the proportion of CD34+ progenitor cells were higher in the group with diverse concentration of growth factor cocktail induction, the proportion of CD34+ cells reached 31.39±3.60% and 73.68±6.63% in day 14 and 21 differentiated BMSC-iPS cells, respectively.Conclusion: In this study, we have clearly demonstrated the generation of putative iPS cells (or partly reprogrammed iPSCs from BMSCs with ectopic high expression of OCT4 by plasmid transfection). The BMSCs-derived iPSCs display the typical morphology and growth pattern as iPS cells when they are maintained in undifferentiated pluripotent state. Moreover, the putative BMSCs-derived iPSCs can differentiate into hematopoietic progenitor cells in defined culture system containing a cocktail of six or seven growth factors. Our findings provide a feasible way to generate hematopoietic progenitor cells using patient-specific iPSCs generated by plasmid transfection for hematological disease modeling.

Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions

Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors

Efficient production of erythroid, megakaryoid and myeloid cells, using single cell-derived iPSC colony differentiation

Enhanced Ex Vivo Generation of Erythroid Cells from Human Induced Pluripotent Stem Cells in a Simplified Cell Culture System with Low Cytokine Support

Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems

Single OCT4 gene introduced into human bone-marrow derived mesenchymal stromal cells can generate putative iPS cells with the potential to differentiate into CD34+ hematopoietic progenitor cells ex vivo

Large-Scale Production of Human iPSC-Derived Macrophages for Drug Screening

Optimized and Scalable Precoating-Free Reprogramming of Human Peripheral Blood Mononuclear Cells into iPSCs

Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521

Generating human bone marrow organoids for disease modeling and drug discovery

Scalable expansion of iPSC and their derivatives across multiple lineages

Human Induced Pluripotent Stem Cell-Derived Bone Marrow Organoids to Model Hematopoietic Development

Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment

A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture

Scalable Production of Human Erythrocytes from Induced Pluripotent Stem Cells

Standardized qc assays and large scale expansion of pluripotent stem cells using an automated closed system.

Automating iPSC generation to enable autologous photoreceptor cell replacement therapy

Highly reproducible and cost-effective one-pot organoid differentiation using a novel platform based on PF-127 triggered spheroid assembly

Extracellular Matrix-Dependent Generation of Integration- and Xeno-Free iPS Cells Using a Modified mRNA Transfection Method

Automated Production at Scale of Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells, Chondrocytes and Extracellular Vehicles: Towards Real-Time Release

Efficient and reproducible generation of human iPSC-derived cardiomyocytes using a stirred bioreactor